Founded as Samyeong Chemical in 1958,
Kolon Pharma became a part of the Kolon Group in 1983.
We manufacture and market healthcare products including prescription drugs,
over-the-counter medications, and health-functional foods.
We are a total healthcare enterprise, actively engaging in new drug research via our orthotopic model-based clinical translational research platform.

Our pharmaceutical division collaborates with top-tier pharmaceutical firms, developing and providing specialty medications in diverse clinical domains such as pulmonology, dermatology, pediatrics, and orthopedics. Moreover, we supply an array of over-the-counter drugs and health-functional foods, including our pioneering gargle-type oral inflammation remedy “Afinibenq” and the three-ingredient constipation solution “Bicogreen S-tablet”. Many of our products consistently rank between 1st to 3rd in market share, testifying to their recognized value.

Our new drug development division continually identifies novel targets via orthotopic modeling and clinical translational research. We ensure precise pre-clinical trials that amplify reproducibility during clinical phases. With these foundations, we aim to elevate the clinical competencies of domestic biotech firms. Our diverse and expandable pipeline has been built through continuous collaboration with various partner entities.

At Kolon Pharma, our vision is to strengthen our pharmaceutical business and new drug development sectors, aspiring to emerge as a global pharma-bio powerhouse.